INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 55 filers reported holding INOZYME PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $394,779 | -19.7% | 93,995 | +6.5% | 0.00% | – |
| Q2 2023 | $491,591 | +418.4% | 88,257 | +433.3% | 0.00% | – |
| Q1 2023 | $94,826 | +445.7% | 16,549 | 0.0% | 0.00% | – |
| Q4 2022 | $17,376 | -61.4% | 16,549 | 0.0% | 0.00% | – |
| Q3 2022 | $45,000 | -43.0% | 16,549 | 0.0% | 0.00% | – |
| Q2 2022 | $79,000 | -36.8% | 16,549 | -45.7% | 0.00% | – |
| Q1 2022 | $125,000 | -49.8% | 30,497 | -16.3% | 0.00% | – |
| Q4 2021 | $249,000 | -41.1% | 36,427 | 0.0% | 0.00% | – |
| Q3 2021 | $423,000 | -59.9% | 36,427 | -41.2% | 0.00% | – |
| Q2 2021 | $1,056,000 | -10.4% | 61,917 | +4.1% | 0.00% | – |
| Q1 2021 | $1,179,000 | +16.4% | 59,495 | +21.3% | 0.00% | – |
| Q4 2020 | $1,013,000 | -20.3% | 49,045 | +1.5% | 0.00% | -100.0% |
| Q3 2020 | $1,271,000 | – | 48,334 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |